Changes of Circulating Tumor Cells Expressing CD90 and EpCAM in Early-Phase of Atezolizumab and Bevacizumab for Hepatocellular Carcinoma

Researchers investigated the cellular characteristics of circulating tumor cells focusing on monitoring during atezolizumab and bevacizumab therapy in patients with HCC. Peripheral blood samples were collected from 10 healthy controls and 40 patients with HCC.